MRC Molecular Haematology Unit
We aim to understand how mature blood cells are normally made from stem cells and how this is perturbed in common blood disorders. Ultimately, our purpose is to improve the prognosis of patients with inherited and acquired blood diseases.
Unit Director
Study With Us
Applications are now open for our 4 year PhD Studentships. Deadline for applications is the 11th January 2019.
Read more‘Family trees’ of AML treated with enasidenib mapped for the first time
The study led by MRC WIMM researchers as part of an international team aims to understand what happens when patients stop responding to treatment.
Read moreNew grant to study pre-cancerous blood disease
Dr Anna Rose at the MRC Molecular Haematology Unit will study disease pathogenesis and prognosis in a subset of patients with Myelodysplastic Syndromes.
Read moreInspiring the next generation of scientists
MRC WIMM hosts its first work experience programme for under-represented students
Read moreLatest Publications
-
A tissue-specific self-interacting chromatin domain forms independently of enhancer-promoter interactions.
Brown JM. et al, (2018), Nat commun, 9
-
Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.
Quevedo CE. et al, (2018), Nat commun, 9
-
How to Tackle Challenging ChIP-Seq, with Long-Range Cross-Linking, Using ATRX as an Example.
Truch J. et al, (2018), Methods mol biol, 1832, 105 - 130
-
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.
Quek L. et al, (2018), Nat med
-
Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome.
Tunstall O. et al, (2018), Br j haematol
Latest News
-
"That’s fascinating!"
22 October 2018
-
Celebrating Women in Science
9 October 2018
-
Deutsche Bank to help fund new Therapy Acceleration Laboratory
25 September 2018
-
New grant to study pre-cancerous blood disease
28 August 2018